MX2024001840A - Composiciones para usar en el tratamiento de neoplasias de celulas b. - Google Patents
Composiciones para usar en el tratamiento de neoplasias de celulas b.Info
- Publication number
- MX2024001840A MX2024001840A MX2024001840A MX2024001840A MX2024001840A MX 2024001840 A MX2024001840 A MX 2024001840A MX 2024001840 A MX2024001840 A MX 2024001840A MX 2024001840 A MX2024001840 A MX 2024001840A MX 2024001840 A MX2024001840 A MX 2024001840A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- malignancy
- subject
- treating
- protein
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 230000036210 malignancy Effects 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 abstract 2
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 abstract 2
- 230000002424 anti-apoptotic effect Effects 0.000 abstract 2
- 238000002648 combination therapy Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 abstract 1
- 201000003791 MALT lymphoma Diseases 0.000 abstract 1
- 102100038732 Mucosa-associated lymphoid tissue lymphoma translocation protein 1 Human genes 0.000 abstract 1
- 101710172604 Mucosa-associated lymphoid tissue lymphoma translocation protein 1 Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
- 230000005945 translocation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción se relaciona con métodos para tratar una neoplasia en un sujeto que lo necesita; el método implica administrar al sujeto una terapia de combinación que comprende: (i) un inhibidor de la proteína de translocación de linfoma de tejido linfoide asociado a la mucosa 1 (MALT1) que tiene la estructura de la Fórmula (I) o una sal, hidrato, polimorfo, o solvatos farmacéuticamente aceptables de este, y (ii) un inhibidor de una proteína antiapoptótica de la familia Bcl-2, donde la terapia de combinación se administra en una cantidad efectiva para tratar la neoplasia en el sujeto; también se describen métodos para reducir los niveles de células T reguladoras en un paciente que padece una neoplasia, así como combinaciones terapéuticas que comprenden un inhibidor de la proteína de translocación de linfoma de tejido linfoide asociado a la mucosa (MALT1) que tiene la estructura de la Fórmula (I) o una sal, hidrato, polimorfo o solvatos farmacéuticamente aceptables de este, y un inhibidor de una proteína antiapoptótica de la familia Bcl-2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163230991P | 2021-08-09 | 2021-08-09 | |
| PCT/EP2022/072257 WO2023016995A1 (en) | 2021-08-09 | 2022-08-08 | Compositions for use in treating b-cell malignancies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001840A true MX2024001840A (es) | 2024-02-28 |
Family
ID=83193300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001840A MX2024001840A (es) | 2021-08-09 | 2022-08-08 | Composiciones para usar en el tratamiento de neoplasias de celulas b. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11872220B2 (es) |
| EP (1) | EP4384171A1 (es) |
| JP (1) | JP2024530204A (es) |
| KR (1) | KR20240046170A (es) |
| CN (1) | CN117794540A (es) |
| AU (1) | AU2022326183A1 (es) |
| CA (1) | CA3227033A1 (es) |
| MX (1) | MX2024001840A (es) |
| WO (1) | WO2023016995A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202207050D0 (en) | 2022-05-13 | 2022-06-29 | C4X Discovery Ltd | Therapeutic compounds |
| WO2025104412A1 (en) | 2023-11-15 | 2025-05-22 | C4X Discovery Limited | Therapeutic compounds |
| WO2025104411A1 (en) | 2023-11-15 | 2025-05-22 | C4X Discovery Limited | Therapeutic compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3794B1 (ar) | 2015-12-10 | 2021-01-31 | Janssen Pharmaceutica Nv | المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| US12269813B2 (en) | 2019-02-22 | 2025-04-08 | Janssen Pharmaceutica Nv | Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-1H-pyrazole-4-carboxamide monohydrate |
-
2022
- 2022-08-08 CN CN202280055199.0A patent/CN117794540A/zh active Pending
- 2022-08-08 EP EP22765019.9A patent/EP4384171A1/en not_active Withdrawn
- 2022-08-08 US US17/882,695 patent/US11872220B2/en active Active
- 2022-08-08 MX MX2024001840A patent/MX2024001840A/es unknown
- 2022-08-08 JP JP2024508092A patent/JP2024530204A/ja active Pending
- 2022-08-08 KR KR1020247003893A patent/KR20240046170A/ko active Pending
- 2022-08-08 CA CA3227033A patent/CA3227033A1/en active Pending
- 2022-08-08 AU AU2022326183A patent/AU2022326183A1/en active Pending
- 2022-08-08 WO PCT/EP2022/072257 patent/WO2023016995A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022326183A1 (en) | 2024-03-28 |
| CA3227033A1 (en) | 2023-02-16 |
| KR20240046170A (ko) | 2024-04-08 |
| EP4384171A1 (en) | 2024-06-19 |
| US11872220B2 (en) | 2024-01-16 |
| CN117794540A (zh) | 2024-03-29 |
| WO2023016995A1 (en) | 2023-02-16 |
| JP2024530204A (ja) | 2024-08-16 |
| US20230074759A1 (en) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024001840A (es) | Composiciones para usar en el tratamiento de neoplasias de celulas b. | |
| JP5767122B2 (ja) | 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬 | |
| EP1002556A2 (en) | Use of MMP inhibitors | |
| JPS59155313A (ja) | 体重の選択的減量のための組成物 | |
| EA200600820A1 (ru) | Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина | |
| ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| WO2001012169A3 (en) | Method of cancer treatment | |
| NZ790364A (en) | Compounds and compositions for use in treating skin disorders | |
| MX2021013942A (es) | Metodos de tratamiento de la urticaria cronica espontanea utilizando un inhibidor de la tirosina quinasa de bruton. | |
| KR20180100309A (ko) | 데옥시콜산 및 이의 염을 사용한 축적된 지방의 치료 방법 | |
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| RU2006123939A (ru) | Лечение остеопороза, связанного с терапией ингибиторами ароматазы | |
| CA3095702A1 (en) | A compound for treating osteoarthritis | |
| WO2022253748A1 (en) | Combinations for the treatment of hpv | |
| CN110051848A (zh) | 药物组合、应用以及抗肿瘤的药物 | |
| MX2023008155A (es) | Regimenes de tratamiento con dosis fijas de tamibaroteno. | |
| MX2023002422A (es) | Farmaco terapeutico para complicaciones motoras en enfermedad de parkinson. | |
| RU2761826C1 (ru) | Композиция для профилактики или лечения рака, включающая разрушающее сосуды средство и таксановое соединение | |
| RU2004131860A (ru) | Комбинированная противоопухолевая терапия, включающая использование замещенных акрилиоилпроизводных дистамицина и лучевой терапии | |
| JP2025523941A (ja) | Ｆｌｔ３阻害剤を含む癌併用療法 | |
| MX2025009650A (es) | Uso del acido (s)-3-amino-4-(difluorometilenil) ciclopent-1-eno-1-carboxilico en el tratamiento de la esclerosis multiple | |
| JP2000506174A (ja) | 殊にガン治療で治療薬として使用するためのシス―４―ヒドロキシ―ｌ―プロリン及びｎ―メチル―シス―４―ヒドロキシ―ｌ―プロリンからなる組合せ物 | |
| MX2025001118A (es) | Terapia de combinacion contra el cancer que incluye un inhibidor de bcl-2 | |
| MX2024016117A (es) | Triazoles para su uso en el tratamiento de enfermedades oculares | |
| Pal et al. | Inflammatory and stem-like colorectal cancer (CRC) subtypes identified in patient-derived xenograft (PDX) models show tumor growth inhibition (TGI) by the combination of trametinib (T) and neratinib (N) irrespective of KRAS mutation (MT) status |